Genmab — Oktober 2019
-
Vores venner SGEN har en god dag. Lad os glædes over deres succes (+15%) i et fase 3 https://finance.yahoo.com/news/seattle-genetics-announces-positive-topline-104500421.html
-
Jeg kommenterer den aktuelle markedssituation med brexit, handelskrig og en mulig recession forude - samt fortæller om mine forventninger til regnskabssæsonen. Det er på TV2 Business i morgen kl. 7.45.
-
Morn fra Bangkok, Synes umidlbart ikke der er noget alarmerende m.h.t genmab kursudvikling. Set ud fra den stigende trendkannal fra Oktober 2018 ligger vi sådanset meget lunt i svinget og hvis vi forbliver i denne kannal burde vi runde 1500kr anytime mellem Nov. 2019 til April 2020 afhængig hvad vel kursen rykker indenfor kanalen.
-
God morgen.
-
from Novartis Q3 | Ofatumumab treatment for RMS showed compelling efficacy across all major clinical endpoints in two pivotal Phase III trials. Rolling regulatory submissions planned to start in Q4 " https://www.novartis.com/news/media-releases/novartis-delivered-another-strong-quarter-double-digit-sales-growth-and-core1-margin-expansion-2019-sales-and-profit-guidance-raised-beovu-launched-us
-
SCHWEIZISK GENMAB-PARTNER OPJUSTERER FOR TREDJE GANG I ÅR
07:36
Genmabs schweiziske partner, Novartis, har tirsdag morgen offentliggjort regnskab for årets tredje kvartal, og det indeholdt årets tredje opjustering.Selskabet venter nu, at der vil være en høj encifret vækst i salget i 2019. Tidligere var forventningen en mellem til høj encifret salgsvækst.
Derudover ventes der nu for kernedriftsindtjeningen en vækst på mid to high teens - 13-19 pct. -
-
Daratumumab treatment for therapy‑refractory anti‑CASPR2
encephalitis https://link.springer.com/article/10.1007/s00415-019-09585-6 in full http://sci-hub.tw/https://link.springer.com/article/10.1007/s00415-019-09585-6 -
-
eller et andet citat, der har mistet al mening "Alt er indregnet" - https://www.youtube.com/watch?v=5S5o20vh63M
-
Bergen Bio stiger 25% lige nu.
Administration (FDA) has approved Fast Track Designation for bemcentinib for the
treatment of elderly patients with acute
myeloid leukaemia (AML) whose disease
has relapsed. There are currently no marketed drugs specifically approved for
all relapsed AML patients, representing a significant unmet medical need.
BerGenBio has ongoing phase 2 trials in this indication and plans to seek
regulatory advice from the FDA and European Medicines Agency (EMA) to determ -
ine
the optimal regulatory path for bemcentinib in relapsed AML. https://classic.nordnet.dk/mux/web/analys/nyheter/visaNyhet.html?itemid=219668008&sourcecode=ob
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind